Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan in Laryngopharyngeal Reflux Disease
KCT0007251Phase 2Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fexuprazan in laryngopharyngeal reflux (LPR) (2 arms), sponsored by Daewoong Pharmaceutical. Started Jun 2022; status: completed.
02
Drugs
fexuprazan
03
Conditions
laryngopharyngeal reflux (LPR)
Beyond the preview
Go deeper on KCT0007251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007251.